MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529162 | Name: Indolidan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Indolidan is a cardiotonic.

Chemical Structure

Indolidan
Indolidan
CAS#100643-96-7

Theoretical Analysis

MedKoo Cat#: 529162

Name: Indolidan

CAS#: 100643-96-7

Chemical Formula: C14H15N3O2

Exact Mass: 257.1164

Molecular Weight: 257.29

Elemental Analysis: C, 65.36; H, 5.88; N, 16.33; O, 12.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Indolidan
IUPAC/Chemical Name
2H-Indol-2-one, 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-
InChi Key
LZCQFJKUAIWHRW-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H15N3O2/c1-14(2)9-7-8(3-4-11(9)15-13(14)19)10-5-6-12(18)17-16-10/h3-4,7H,5-6H2,1-2H3,(H,15,19)(H,17,18)
SMILES Code
O=C1NC2=C(C=C(C(CC3)=NNC3=O)C=C2)C1(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 257.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Haynes J Jr, Obiako B, Babal P, Stevens T. 5-(N-ethylcarboxamido)adenosine desensitizes the A2b-adenosine receptor in lung circulation. Am J Physiol. 1999 Jun;276(6 Pt 2):H1877-83. PubMed PMID: 10362666. 2: Naka Y, Roy DK, Liao H, Chowdhury NC, Michler RE, Oz MC, Pinsky DJ. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res. 1996 Oct;79(4):773-83. PubMed PMID: 8831501. 3: Ashikaga T, Robertson DW, Sportsman RJ, Strada SJ, Thompson WJ. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):315-37. PubMed PMID: 8968964. 4: Rousseau E, Dostie J, Taoudi-Benchekroun M, Cadieux A, Beaudry C, Lugnier C. Specific cyclic nucleotide phosphodiesterase inhibitors differently modulate contractile kinetics in airway smooth muscle. Can J Physiol Pharmacol. 1995 Dec;73(12):1784-94. PubMed PMID: 8834493. 5: Tischler AS, Riseberg JC, Gray R. Mitogenic and antimitogenic effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in adult rat chromaffin cell cultures. Neurosci Lett. 1995 Apr 21;189(3):135-8. PubMed PMID: 7624029. 6: Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VW. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res. 1995 Feb;76(2):199-208. PubMed PMID: 7834830. 7: Rousseau E, Gagnon J, Lugnier C. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium. Mol Cell Biochem. 1994 Nov 23;140(2):171-5. PubMed PMID: 7898488. 8: Pinsky D, Oz M, Liao H, Morris S, Brett J, Sciacca R, Karakurum M, Van Lookeren Campagne M, Platt J, Nowygrod R, et al. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest. 1993 Dec;92(6):2994-3002. PubMed PMID: 8254053; PubMed Central PMCID: PMC288503. 9: Sandusky GE, Means JR, Yeager HK. Coronary artery toxicity in beagle dogs given indolidan, a type III phosphodiesterase inhibitor. Fundam Appl Toxicol. 1993 Aug;21(2):228-35. PubMed PMID: 8405786. 10: Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther. 1993 Jun;265(3):1142-51. PubMed PMID: 8389853. 11: Shaffer JE, Grizzle MK, Anderson DK, Wheeler TN. The inotropic and beta blocking effects of a chimeric molecule that putatively inhibits both type III phosphodiesterase and beta adrenoceptors in anesthetized dogs. J Pharmacol Exp Ther. 1993 Jun;265(3):1105-12. PubMed PMID: 8099617. 12: Mochizuki N, Uchida S, Miyata H. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties. J Cardiovasc Pharmacol. 1993 Jun;21(6):983-95. PubMed PMID: 7687727. 13: Law PY, Loh HH. delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells. Mol Pharmacol. 1993 May;43(5):684-93. PubMed PMID: 8388986. 14: Corder CN, Puls A, Wilson M. Clinical effect of indolidan in congestive heart failure. Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):405-9. PubMed PMID: 1446958. 15: Oquist NL, Strada SJ, Artman M. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium. Pediatr Res. 1992 Mar;31(3):300-4. PubMed PMID: 1313959. 16: Haynes J Jr, Kithas PA, Taylor AE, Strada SJ. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am J Physiol. 1991 Aug;261(2 Pt 2):H487-92. PubMed PMID: 1652213. 17: Moore JB Jr, Combs DW, Tobia AJ. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue. Biochem Pharmacol. 1991 Jul 15;42(3):679-83. PubMed PMID: 1650219. 18: Nomoto Y, Takai H, Ohno T, Kubo K. Studies on cardiotonic agents. VI. Synthesis of novel 4,5-dihydro-3(2H)-pyridazinone derivatives carrying some benzoheterocycles at the 6-position. Chem Pharm Bull (Tokyo). 1991 Feb;39(2):352-7. PubMed PMID: 2054859. 19: Sandusky GE Jr, Vodicnik MJ, Tamura RN. Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fundam Appl Toxicol. 1991 Jan;16(1):198-209. PubMed PMID: 2019345. 20: Fischmeister R, Hartzell HC. Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells. Mol Pharmacol. 1990 Sep;38(3):426-33. PubMed PMID: 1698253.

View History

Irsenontrine maleate

Irsenontrine maleate